Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Evaluating mesothelin as an immunotherapeutic target for endogenous T cells.

Frontiers in immunology·2026
Same author

Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy.

Cell reports. Medicine·2026
Same author

See Me, Support Me: A platform for student voice can unlock teachers' support for English language learner students in the entrance to high school.

Cultural diversity & ethnic minority psychology·2026
Same author

Engineering Functionality Optimized fully human B7-H3 CAR T Cells for Enhanced Solid Tumor Therapy.

bioRxiv : the preprint server for biology·2026
Same author

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.

Nature medicine·2026
Same author

ANTXR1 blockade enhances cardiac function in preclinical models of heart failure.

Nature cardiovascular research·2025

相关实验视频

Updated: Sep 15, 2025

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.9K

武装IL-7的二进制CAR T细胞策略,以增强对抗固体瘤的功效.

Alejandro G Torres Chavez1, Mary K McKenna1, Anmol Gupta2

  • 1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.

bioRxiv : the preprint server for biology
|July 16, 2025
PubMed
概括

这项研究引入了一种针对PSCA和MUC1的新型双CAR T细胞疗法,以克服固体瘤中的抗原损失. 在胰腺癌模型中,表达IL-7和IL-7Rα的工程T细胞表现出强大而持久的抗瘤作用.

关键词:
化学抗原受体的化学抗原受体在IL-7中,IL-7是最常见的.在IL-7R中,IL-7R是最常见的.固体瘤是一个固体瘤.通过T细胞治疗治疗.

更多相关视频

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

811

相关实验视频

Last Updated: Sep 15, 2025

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.9K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

811

科学领域:

  • 免疫疗法是一种免疫疗法.
  • 在瘤学瘤学.
  • 细胞工程 细胞工程

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法对B细胞恶性瘤有希望,但在固体瘤中面临挑战.
  • 在CAR T细胞治疗中复发通常是由于抗原损失和T细胞持久性差的结果.
  • 固体瘤具有独特的障碍,包括抗原异质性和免疫抑制,限制了CAR T细胞的疗效.

研究的目的:

  • 开发一种针对PSCA和MUC1的双重CAR T细胞战略,以解决固体瘤中的抗原异质性问题.
  • 增强瘤微环境中的T细胞持久性和抗瘤活性.
  • 在临床前胰腺癌模型中评估这种二进制CAR T细胞方法的疗效.

主要方法:

  • 工程T细胞具有独立的CAR,针对PSCA和MUC1.
  • 转基因IL-7细胞因子和受体 (IL-7Rα) 的联合表达,以促进局部T细胞的持久性.
  • 在胰腺瘤模型中评估双重CAR T细胞策略的效力和耐久性.

主要成果:

  • 双重CAR T细胞策略有效地针对PSCA和MUC1抗原.
  • 工程T细胞表现出增强的持久性和局部抗瘤活性.
  • 在胰腺瘤模型中表现出强大而持久的抗瘤作用.

结论:

  • 针对PSCA和MUC1的双重CAR T细胞策略,结合IL-7/IL-7Rα联合表达,为固体瘤提供了一个有前途的方法.
  • 这种二元策略有效地克服了抗原异质性,并增强了T细胞的寿命.
  • 这些发现支持这种增强的CAR T细胞疗法在胰腺癌治疗中的潜力.